Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1402, USA.
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):390-5. doi: 10.1016/j.ijrobp.2011.11.073. Epub 2012 Feb 17.
To investigate whether the volumes of rectum exposed to intermediate doses, from 30 to 50 Gy, contribute to the risk of Grade ≥ 2 late rectal toxicity among patients with prostate cancer receiving radiotherapy.
Data from 1009 patients treated on Radiation Therapy Oncology Group protocol 94-06 were analyzed using three approaches. First, the contribution of intermediate doses to a previously published fit of the Lyman-Kutcher-Burman (LKB) normal tissue complication probability (NTCP) model was determined. Next, the extent to which intermediate doses provide additional risk information, after taking the LKB model into account, was investigated. Third, the proportion of rectum receiving doses higher than a threshold, VDose, was computed for doses ranging from 5 to 85 Gy, and a multivariate Cox proportional hazards model was used to determine which of these parameters were significantly associated with time to Grade ≥ 2 late rectal toxicity.
Doses <60 Gy had no detectable impact on the fit of the LKB model, as expected on the basis of the small estimate of the volume parameter (n = 0.077). Furthermore, there was no detectable difference in late rectal toxicity among cohorts with similar risk estimates from the LKB model but with different volumes of rectum exposed to intermediate doses. The multivariate Cox proportional hazards model selected V75 as the only value of VDose significantly associated with late rectal toxicity.
There is no evidence from these data that intermediate doses influence the risk of Grade ≥ 2 late rectal toxicity. Instead, the critical doses for this endpoint seem to be ≥ 75 Gy. It is hypothesized that cases of Grade ≥ 2 late rectal toxicity occurring among patients with V75 less than approximately 12% may be due to a "background" level of risk, likely due mainly to biological factors.
研究接受放疗的前列腺癌患者直肠接受 30 至 50 Gy 中等剂量照射的体积是否会导致≥2 级晚期直肠毒性的风险增加。
对 1009 例接受放射治疗肿瘤学组 94-06 号方案治疗的患者的数据进行了分析,采用了三种方法。首先,确定中间剂量对之前发表的 Lyman-Kutcher-Burman(LKB)正常组织并发症概率(NTCP)模型拟合的贡献。其次,在考虑 LKB 模型后,研究中间剂量提供额外风险信息的程度。第三,计算直肠接受高于阈值 VDose 的剂量的比例,剂量范围从 5 到 85 Gy,并使用多变量 Cox 比例风险模型来确定这些参数中哪些与≥2 级晚期直肠毒性的时间显著相关。
正如预期的那样,由于体积参数的估计值很小(n=0.077),剂量<60 Gy 对 LKB 模型的拟合没有可检测到的影响。此外,在 LKB 模型具有相似风险估计值但直肠接受中等剂量照射的体积不同的队列中,晚期直肠毒性没有可检测到的差异。多变量 Cox 比例风险模型选择 V75 作为唯一与晚期直肠毒性显著相关的 VDose 值。
这些数据没有证据表明中间剂量会影响≥2 级晚期直肠毒性的风险。相反,对于这个终点的关键剂量似乎是≥75 Gy。据推测,V75 小于约 12%的患者发生≥2 级晚期直肠毒性的病例可能是由于“背景”风险水平,可能主要归因于生物学因素。